Copyright
©The Author(s) 2020 Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 14, 2020; 26(30): 4428-4441
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4428
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4428
Table 3 Remission at 6 mo and 12 mo of vedolizumab therapy
| Total | Australia | Oxford | P value | |
| Remission at 6 mo, n (%) | 147 (62) | 110/173(64) | 37/65 (57) | 0.34 |
| Remission at 12 mo, n (%) | 120/201 (60) | 87/138 (63) | 33/65 (52) | 0.09 |
| Total | Anti-TNF naive | Anti-TNF exposed | ||
| Remission at 6 mo, n (%) | 147/238 (62) | 103/142 (73) | 44/96 (46) | < 0.001 |
| Remission at 12 mo, n (%) | 120/201 (60) | 76/115 (66) | 44/86 (51) | 0.03 |
| Anti-TNF exposed | Primary LOR | Secondary LOR | ||
| Remission at 6 mo, n (%) | 44/96 (46) | 16/42 (38) | 28/54 (52) | 0.18 |
| Remission at 12 mo, n (%) | 44/86 (51) | 17/38 (44) | 27/48 (56) | 0.28 |
- Citation: Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441
- URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4428.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4428